BioCardia Announces FDA Confirmation Supporting Follow‑On De Novo Pre‑Submission

What Happened
On August 24, 2026, BioCardia, Inc. (BCDA) issued a press release and filed a Form 8‑K (Item 7.01) announcing that the U.S. Food and Drug Administration (FDA) has confirmed the meeting minutes for the Helix Transendocardial Delivery Catheter. The company says this confirmation supports a follow‑on De Novo pre‑submission pathway toward potential regulatory approval. The press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Date of disclosure: August 24, 2026 (Form 8‑K filing and press release).
• Product: Helix Transendocardial Delivery Catheter.
• Regulatory update: FDA confirmed the meeting minutes, which BioCardia says support a follow‑on De Novo pre‑submission for approval.
• Exhibit filed: Press release included as Exhibit 99.1 to the Form 8‑K.

Why It Matters
This is a regulatory progress update — confirmation of meeting minutes by the FDA can clarify the agency’s feedback and next steps for a De Novo pathway, which is a route for certain novel medical devices to seek marketing authorization. For investors, the item is material as it relates to the company’s product development and potential path to commercialization, but the filing does not provide timing, financial impacts, or a guarantee of approval. Investors should watch for subsequent filings or FDA communications for more detailed milestones, review timelines, and any clinical or regulatory decisions.